

IN THE CLAIMS

1. (currently amended): The method of ~~improving FMF control, in humans,~~
treating Familian Mediterranean Fever (FMF) in a patient suffering from FMF, which
~~includes~~ comprises orally administering, on an average daily basis, ~~for at least 5~~
~~months,~~ between 5 and 15 milligrams of ~~LTRA~~ leukotriene receptor antagonist
(LTRA) selected from the group consisting of 4-5-cyclopentyloxy-carbonylamino-1-
methyl-indol-3-ylmethyl-3-methoxy-N-o-tonylsulfanylbenzamide and montelukant
sodium to [a] said patient suffering from FMF, for treatment only of FMF and
continuing said administration as long as the FMF symptoms continue.

2. (canceled)

3. (currently amended): The method of claim [2] 1 wherein said LTRA is
administrated orally in tablet form.

4. (original): The method of claim 1 wherein about 10 milligrams of said LTRA is
administered, on a daily basis.

5. (currently amended): The method of claim 1 wherein said ~~humans are~~ patient
is between 9 and 72 years old.

6. (currently amended): The method of claim [2] 1 wherein said LTRA consists
of ZAFIRLUCAST tablets.

7. (currently amended): The method of claim [2] 1 wherein said LTRA consists
of SINGULAIR tablets.